The Voice of the Global Clinical Research Industry
The Association of Clinical Research Organizations (ACRO) represents companies on the forefront of global clinical research. ACRO members are committed to innovation in clinical development and thought leadership in research policy on topics like RBM and RBQM.
Half of all clinical trials occur in the US. ACRO works with US legislators and regulators to ensure a positive regulatory environment that supports high-quality, safe and ethical clinical research. More »
ACRO engages with European regulators, connecting its members with critical stakeholders. We support the clinical research industry and provide CRO expertise. More »
ACRO’s CRO Forum is a formal mechanism to enable clinical research organizations to interact with TransCelerate BioPharma Inc. on a range of issues that impact the industry. More »
Clinical Research Roundtables
In Europe and the US, ACRO gathers government leaders and key stakeholders to inform, educate and promote the unique contributions of clinical research and technology companies. More »
Addressing Industry Pain Points
We help create a predictable, enabling business environment. ACRO’s proactive agenda is focused on policy outcomes that advance specific operational interests of ACRO members. More »
Data Protection & Privacy
ACRO’s Global Data Protection & Privacy Committee advances issues of data privacy, protection and security, and how the industry interprets policies and prepares for upcoming legislation. More »
Get ACRO’s free quarterly newsletter to stay informed about our work and the industry.
Join ACRO and Add Your Voice
We help create a global regulatory and business environment where ACRO members succeed
On July 17, 2019, under cooperative agreement with the FDA, the Duke-Margolis Center for Health Policy (Duke Margolis) held a public workshop. The event, titled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations, aimed to identify opportunities to improve Risk Based Monitoring (RBM) implementation and solicit stakeholder input on the challenges, barriers, and enablers that impact the successful adoption of RBM.
Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies.